The TaurusTrio TAV system is developed and manufactured by Peijia Medical under an exclusive license from JenaValve Technology, Inc. (JenaValve) for its Trilogy Transcatheter Heart Valve (THV) System. It is designed to treat patients with native symptomatic severe aortic regurgitation (AR) via transfemoral access. Unlike in patients with aortic stenosis, in patients with AR, there is often no calcification for the TAV to anchor onto, leaving AR patients with limited treatment options. The TaurusTrio system incorporates JenaValve’s proprietary locator technology, which enables stable anchoring by engaging the native aortic leaflets even in the absence of calcium, while ensuring commissural alignment. 

The one-year clinical results from the TaurusTrio ALTER-AR study demonstrated a technical success rate of 99.1%, with 0% all-cause mortality at 30 days and only 2.6% at one year. Patients showed significant cardiac function improvement, with 91.7% recovering to NYHA class I/II at six months. The incidence of moderate or greater paravalvular leak was 0% at one year, and indicators such as LVEDV and LVM showed significant reverse remodeling, validating the device’s long-term safety and efficacy.